Sarcopenia: Prevalence and Prognostic Implications in Elderly Patients with Cardiovascular Disease
Aims Sarcopenia has recently been given an ICD‐10 code. However, there have been no systematic investigations regarding the prevalence or prognostic value of sarcopenia in cardiovascular disease (CVD) according to the international consensus definition. The present study was performed to investigate...
Gespeichert in:
Veröffentlicht in: | JCSM clinical reports 2017-07, Vol.2 (2), p.1-13 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Aims
Sarcopenia has recently been given an ICD‐10 code. However, there have been no systematic investigations regarding the prevalence or prognostic value of sarcopenia in cardiovascular disease (CVD) according to the international consensus definition. The present study was performed to investigate the prevalence and prognostic value of sarcopenia in elderly patients with CVD.
Methods and results
The study population consisted of 1603 admitted patients aged ≥ 65 years (74.4 ± 6.2 years, 1049 men) with CVD. Sarcopenia was defined according to the recommended diagnostic algorithm of the Asia Working Group for Sarcopenia. The endpoint for the study was all‐cause mortality. The overall sarcopenia prevalence rate was 29.7% (19.6% in men and 48.7% in women). The prevalence rates of sarcopenia across major diagnostic categories were as follows: acute coronary syndrome, 17.8%; post‐cardiac surgery, 31.8%; and heart failure, 35.2%. During the 2.3 ± 2.1‐year follow‐up period, 175 deaths occurred. Patients with sarcopenia showed higher risk of all‐cause mortality compared with non‐sarcopenic patients (adjusted hazard ratio: 1.44; 95% confidence interval: 1.01 – 2.05; P = 0.044).
Conclusions
Sarcopenia is highly prevalent among elderly patients with CVD and is associated with increased mortality risk. |
---|---|
ISSN: | 2521-3555 2521-3555 |
DOI: | 10.17987/jcsm-cr.v2i2.41 |